Jin Ying-Ying, Zhou Wei, Tian Zhi-Qing, Chen Tong-Xin
Department of Allergy and Immunology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Department of Nephrology and Rheumatology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Hum Immunol. 2016 Aug;77(8):658-666. doi: 10.1016/j.humimm.2016.06.005. Epub 2016 Jun 8.
X-linked lymphoproliferative disease (XLP) is a rare life-threatening syndrome. Rapid recognition and definitive diagnosis are critical to improve the prognosis and survival of patients with XLP. Nowadays, little is known about patients with XLP in China.
We report the characterization of five Chinese XLP patients with three novel mutations and review the literature related to this syndrome. Male patients with fulminant infectious mononucleosis (FIM), Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) or persistent EBV viraemia were enrolled in this study. The patients' clinical features were assessed by retrieval of data from medical records. Immunological function included analysis of lymphocyte subsets and the detection of immunoglobulins G, A, M and/or E were evaluated by flow cytometry and nephelometry. Direct sequencing was used to detect SH2D1A/XIAP gene mutations.
Twenty-two male patients with FIM, EBV-associated HLH or persistent EBV viraemia were evaluated among 421 PID patients in our centre. Four patients had SH2D1A mutations, and one patient had an XIAP mutation. The onset age of the 5 patients range from 1month to 4years which was earlier than that in the western world. The diagnosis age was between 16months and 9years with a long diagnosis lag (1-97months). Two of them had positive family history. The clinical phenotypes varied in different patients among which two patients with FHLH and hypogammaglobulinaemia, one with hypogammaglobulinaemia, lymphoma and aplastic anaemia (AA) which is the first case with AA in China, one with hypogammaglobulinaemia only and the other one with FHLH. For immunological function, three exhibited reduced CD4/CD8 ratios. Arg55stop mutations as well as splice mutation in intron 1 were most frequently found and exon 2 was the hottest exon in China. Two patients died at the time of diagnosis for severe infection or hepatic coma. Three were alive and waiting for haematopoietic stem cell transplantation (HSCT).
For patients with severe EBV-associated HLH, hypogammaglobulinaemia, lymphoma and aplastic anaemia, possibility of XLP should be considered and if confirmed, HSCT should be performed as soon as possible.
X连锁淋巴增生性疾病(XLP)是一种罕见的危及生命的综合征。快速识别和明确诊断对于改善XLP患者的预后和生存率至关重要。目前,中国关于XLP患者的了解甚少。
我们报告了5例中国XLP患者的特征,其中有3种新的突变,并回顾了与该综合征相关的文献。本研究纳入了患有暴发性传染性单核细胞增多症(FIM)、爱泼斯坦-巴尔病毒(EBV)相关噬血细胞性淋巴组织细胞增生症(HLH)或持续性EBV病毒血症的男性患者。通过查阅病历数据评估患者的临床特征。免疫功能包括淋巴细胞亚群分析以及通过流式细胞术和比浊法检测免疫球蛋白G、A、M和/或E。采用直接测序法检测SH2D1A/XIAP基因突变。
在我们中心的421例原发性免疫缺陷病(PID)患者中,评估了22例患有FIM、EBV相关HLH或持续性EBV病毒血症的男性患者。4例患者有SH2D1A突变,1例患者有XIAP突变。这5例患者的发病年龄在1个月至4岁之间,早于西方世界。诊断年龄在16个月至9岁之间,诊断延迟时间较长(1 - 97个月)。其中2例有家族史阳性。不同患者的临床表型各不相同,其中2例患有家族性噬血细胞性淋巴组织细胞增生症(FHLH)和低丙种球蛋白血症,1例患有低丙种球蛋白血症、淋巴瘤和再生障碍性贫血(AA),这是中国首例AA病例,1例仅患有低丙种球蛋白血症,另1例患有FHLH。免疫功能方面,3例患者的CD4/CD8比值降低。在中国,最常发现的是Arg55stop突变以及内含子1的剪接突变,外显子2是热点外显子。2例患者在诊断时因严重感染或肝昏迷死亡。3例患者存活,等待造血干细胞移植(HSCT)。
对于患有严重EBV相关HLH、低丙种球蛋白血症、淋巴瘤和再生障碍性贫血的患者,应考虑XLP的可能性,一旦确诊,应尽快进行HSCT。